JP2014503482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503482A5 JP2014503482A5 JP2013537154A JP2013537154A JP2014503482A5 JP 2014503482 A5 JP2014503482 A5 JP 2014503482A5 JP 2013537154 A JP2013537154 A JP 2013537154A JP 2013537154 A JP2013537154 A JP 2013537154A JP 2014503482 A5 JP2014503482 A5 JP 2014503482A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- domain
- immunoglobulin
- hypervariable regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41053310P | 2010-11-05 | 2010-11-05 | |
| US61/410,533 | 2010-11-05 | ||
| PCT/EP2011/069476 WO2012059598A2 (en) | 2010-11-05 | 2011-11-04 | Methods of treating rheumatoid arthritis using il-17 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015232562A Division JP6049843B2 (ja) | 2010-11-05 | 2015-11-30 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503482A JP2014503482A (ja) | 2014-02-13 |
| JP2014503482A5 true JP2014503482A5 (enExample) | 2014-12-18 |
Family
ID=44906168
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537154A Pending JP2014503482A (ja) | 2010-11-05 | 2011-11-04 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2015232562A Active JP6049843B2 (ja) | 2010-11-05 | 2015-11-30 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2016139469A Active JP6250109B2 (ja) | 2010-11-05 | 2016-07-14 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2017223669A Active JP6515168B2 (ja) | 2010-11-05 | 2017-11-21 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2019076324A Pending JP2019142912A (ja) | 2010-11-05 | 2019-04-12 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2021031383A Pending JP2021104995A (ja) | 2010-11-05 | 2021-03-01 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2023084472A Pending JP2023109910A (ja) | 2010-11-05 | 2023-05-23 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2025034128A Pending JP2025102772A (ja) | 2010-11-05 | 2025-03-04 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015232562A Active JP6049843B2 (ja) | 2010-11-05 | 2015-11-30 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2016139469A Active JP6250109B2 (ja) | 2010-11-05 | 2016-07-14 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2017223669A Active JP6515168B2 (ja) | 2010-11-05 | 2017-11-21 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2019076324A Pending JP2019142912A (ja) | 2010-11-05 | 2019-04-12 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2021031383A Pending JP2021104995A (ja) | 2010-11-05 | 2021-03-01 | Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2023084472A Pending JP2023109910A (ja) | 2010-11-05 | 2023-05-23 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
| JP2025034128A Pending JP2025102772A (ja) | 2010-11-05 | 2025-03-04 | Ｉｌ－１７アンタゴニストを用いて関節リウマチを治療する方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (11) | US9744234B2 (enExample) |
| EP (6) | EP4116325B1 (enExample) |
| JP (8) | JP2014503482A (enExample) |
| KR (5) | KR20150020734A (enExample) |
| CN (2) | CN103189074A (enExample) |
| AU (1) | AU2011325134B2 (enExample) |
| BR (1) | BR112013011176A2 (enExample) |
| CA (2) | CA2813849C (enExample) |
| CL (1) | CL2013001213A1 (enExample) |
| CY (1) | CY1121802T1 (enExample) |
| DE (1) | DE20187001T1 (enExample) |
| DK (2) | DK3111954T3 (enExample) |
| ES (3) | ES2804624T3 (enExample) |
| FI (1) | FI3757126T3 (enExample) |
| HR (2) | HRP20251174T1 (enExample) |
| HU (1) | HUE044038T2 (enExample) |
| IL (4) | IL311014A (enExample) |
| LT (2) | LT3757126T (enExample) |
| MA (1) | MA34647B1 (enExample) |
| MX (1) | MX362591B (enExample) |
| PH (1) | PH12013500890A1 (enExample) |
| PL (1) | PL3111954T3 (enExample) |
| PT (2) | PT3757126T (enExample) |
| RS (1) | RS67377B1 (enExample) |
| RU (1) | RU2582937C2 (enExample) |
| SG (2) | SG10201505624VA (enExample) |
| SI (2) | SI3757126T1 (enExample) |
| SM (1) | SMT202500423T1 (enExample) |
| TR (1) | TR201909531T4 (enExample) |
| TW (3) | TWI616204B (enExample) |
| WO (1) | WO2012059598A2 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012013490A (es) | 2010-05-20 | 2013-01-29 | Ablynx Nv | Materiales biologicos relacionados con her3. |
| RU2665954C1 (ru) | 2010-10-08 | 2018-09-05 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| TWI616204B (zh) | 2010-11-05 | 2018-03-01 | 諾華公司 | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| KR20220116585A (ko) | 2011-10-11 | 2022-08-23 | 비엘라 바이오, 인크. | Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법 |
| WO2013116682A1 (en) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| CN105899231A (zh) * | 2013-10-22 | 2016-08-24 | 诺夫免疫股份有限公司 | 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物 |
| JP2017508446A (ja) * | 2014-01-28 | 2017-03-30 | 北京韓美薬品有限公司 | 二機能性融合タンパク質及びその製造方法並びに使用 |
| EP3142751B1 (en) | 2014-05-13 | 2019-08-07 | MedImmune Limited | Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer |
| US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| CA2949236C (en) | 2014-05-15 | 2023-06-13 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
| FR3021976B1 (fr) * | 2014-06-06 | 2018-11-02 | Hospices Civils De Lyon | Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu |
| US20160002326A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Compositions and methods for treating rheumatoid arthritis |
| NL2013007B1 (en) * | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| US11278618B2 (en) | 2014-09-10 | 2022-03-22 | Novartis Ag | Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients |
| JP6675394B2 (ja) * | 2014-10-22 | 2020-04-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 疾患及び障害の治療のためにインターロイキン−１０を使用する方法 |
| AR103172A1 (es) * | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| HK1247622A1 (zh) | 2015-03-02 | 2018-09-28 | 180 Therapeutics Lp | 利用il-33拮抗剂来治疗局部纤维化的方法 |
| EP3167892A1 (en) | 2015-11-10 | 2017-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases |
| JP6858766B2 (ja) * | 2015-10-19 | 2021-04-14 | ノバルティス アーゲー | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| JP2019534240A (ja) * | 2016-08-23 | 2019-11-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法 |
| WO2019087133A1 (en) * | 2017-11-02 | 2019-05-09 | Novartis Ag | Method of treating tendinopathy using interleukin-17 (il-17) |
| GB201719447D0 (en) * | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| CN112584857A (zh) * | 2018-05-09 | 2021-03-30 | 诺华股份有限公司 | 卡那吉努单抗的用途 |
| JP7596261B2 (ja) * | 2018-09-26 | 2024-12-09 | ビエラ バイオ インコーポレイテッド | Ｃｄ４０ｌアンタゴニスト及びその使用 |
| CN118453606A (zh) * | 2019-01-22 | 2024-08-09 | 豪夫迈·罗氏有限公司 | 使用布鲁顿氏酪氨酸激酶抑制剂来治疗类风湿性关节炎、慢性自发性荨麻疹和系统性红斑狼疮的方法 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| CN110179746A (zh) | 2019-05-17 | 2019-08-30 | 通化东宝生物科技有限公司 | 一种稳定的苏金单抗注射剂及其制备方法 |
| CN115515610A (zh) * | 2019-08-05 | 2022-12-23 | 伊夫罗生物科学公司 | 使用栖组织普雷沃菌治疗银屑病和特应性皮炎的组合物和方法 |
| CA3155108A1 (en) * | 2019-09-20 | 2021-03-25 | Novartis Ag | Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists |
| JP2023502103A (ja) | 2019-11-19 | 2023-01-20 | ノバルティス アーゲー | インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法 |
| CN112915201B (zh) * | 2019-12-06 | 2023-06-27 | 珠海市丽珠单抗生物技术有限公司 | 包含抗il-17抗体的液体制剂 |
| WO2021146850A1 (en) * | 2020-01-20 | 2021-07-29 | Tsinghua University | A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4 |
| EP4251197A4 (en) * | 2020-11-25 | 2024-10-23 | Dr. Reddy's Laboratories Ltd. | STABLE THERAPEUTIC PROTEIN FORMULATION AND METHODS OF MANUFACTURE THEREOF |
| WO2022144023A1 (zh) * | 2021-01-04 | 2022-07-07 | 江苏恒瑞医药股份有限公司 | 抗il-17抗体治疗自身免疫性疾病和炎症的方法 |
| TW202246329A (zh) * | 2021-03-03 | 2022-12-01 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 抗il-17抗體治療自體免疫性疾病和炎症的方法 |
| KR102339377B1 (ko) * | 2021-03-29 | 2021-12-13 | 김지혜 | 사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치 |
| CN117500834A (zh) * | 2021-06-21 | 2024-02-02 | 百时美施贵宝公司 | 使用蔗糖、甘露糖醇和甘氨酸来减少高浓度冻干生物制剂药物产品的重构时间 |
| CN114306594A (zh) * | 2021-12-21 | 2022-04-12 | 华中科技大学同济医学院附属协和医院 | 地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用 |
| WO2024156841A1 (en) | 2023-01-27 | 2024-08-02 | Fresenius Kabi Deutschland Gmbh | Biopharmaceutical composition |
| EP4406553A1 (en) | 2023-01-27 | 2024-07-31 | Fresenius Kabi Deutschland GmbH | Stable secukinumab biopharmaceutical composition |
| AU2024353756A1 (en) * | 2023-09-27 | 2026-05-07 | Samsung Bioepis Co., Ltd. | Stable liquid formulation of anti-il-17 antibody |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0565233A (ja) | 1991-03-08 | 1993-03-19 | Mitsui Toatsu Chem Inc | モノクローナル抗体含有凍結乾燥製剤 |
| US5250442A (en) | 1993-04-08 | 1993-10-05 | Orestes Cabezas | Method of treating rheumatoid arthritis using tetracycline |
| US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US20050147609A1 (en) | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
| JP2000186046A (ja) | 1998-10-14 | 2000-07-04 | Snow Brand Milk Prod Co Ltd | 慢性関節リウマチ治療剤及び診断方法 |
| JP4813660B2 (ja) | 1998-11-27 | 2011-11-09 | ダーウィン ディスカバリー リミテッド | 骨鉱化作用を増加するための組成物および方法 |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| JP4159682B2 (ja) | 1998-12-22 | 2008-10-01 | 株式会社クラレ | 止血材 |
| AU2002324556A1 (en) | 2001-07-25 | 2003-02-17 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| MXPA04004459A (es) | 2001-11-09 | 2005-05-16 | Johnson & Johnson | Composiciones liofilizadas de anticuerpo monoclonal. |
| US7332276B2 (en) | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| US6974701B2 (en) | 2003-03-21 | 2005-12-13 | Hemovations, Llc | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same |
| US7381409B2 (en) | 2003-06-16 | 2008-06-03 | Celltech R&D, Inc. | Antibodies specific for sclerostin and methods of screening and use therefor |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8039642B2 (en) | 2003-12-09 | 2011-10-18 | Life Technologies Corporation | Pyrenyloxysulfonic acid fluorescent agents |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JP3936365B2 (ja) | 2004-09-14 | 2007-06-27 | ソニーケミカル＆インフォメーションデバイス株式会社 | 機能素子実装モジュール及びその製造方法 |
| LT2620450T (lt) | 2005-03-08 | 2019-02-11 | Pfizer Products Inc. | Anti-ctla-4 antikūnų kompozicijos |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP1957474A4 (en) | 2005-11-04 | 2011-08-24 | Harvard College | SYNTHESIS OF FTSZ HEMMERN |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| CN101374864A (zh) | 2006-01-31 | 2009-02-25 | 诺瓦提斯公司 | 用于靶向癌症的il-17拮抗性抗体 |
| TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
| KR20090088852A (ko) | 2006-09-05 | 2009-08-20 | 메다렉스, 인코포레이티드 | 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법 |
| JPWO2008029908A1 (ja) | 2006-09-07 | 2010-01-21 | 協和発酵キリン株式会社 | 抗体を含有する安定な凍結乾燥医薬製剤 |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| CN101541833B (zh) * | 2006-10-02 | 2014-01-29 | 麒麟-安姆根有限公司 | Il-17受体a抗原结合蛋白质 |
| WO2008061013A2 (en) | 2006-11-10 | 2008-05-22 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| EA200901031A1 (ru) | 2007-02-02 | 2010-04-30 | Новартис Аг | Модуляторы склеростин-связывающих партнеров для лечения костных расстройств |
| KR101123487B1 (ko) | 2007-03-20 | 2012-03-23 | 일라이 릴리 앤드 캄파니 | 항?스클레로스틴 항체 |
| MX2009010179A (es) | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| US20100209434A1 (en) | 2007-03-30 | 2010-08-19 | Medimmune, Llc | Antibody formulation |
| JP5237366B2 (ja) * | 2007-06-20 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 炎症性関節疾患に対する抗ｉｌ−１７ａ治療のための関節破壊のバイオマーカー |
| US7720605B2 (en) | 2007-06-22 | 2010-05-18 | Weyerhaeuser Nr Company | Identifying vegetation attributes from LiDAR data |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| JP2011506483A (ja) | 2007-12-14 | 2011-03-03 | アムジエン・インコーポレーテツド | 抗スクレロスチン抗体を用いた骨折の治療方法 |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US20090301682A1 (en) | 2008-06-05 | 2009-12-10 | Baker Hughes Incorporated | Casting furnace method and apparatus |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| KR101318549B1 (ko) | 2008-09-29 | 2013-10-16 | 로슈 글리카트 아게 | 인간 ｉｌ17 에 대한 항체 및 이의 용도 |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| FR2938547B1 (fr) | 2008-11-14 | 2012-11-16 | Total Raffinage Marketing | Liant synthetique clair |
| WO2010065491A2 (en) | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| TW201613969A (en) | 2009-03-05 | 2016-04-16 | Abbvie Inc | IL-17 binding proteins |
| RU2665954C1 (ru) | 2010-10-08 | 2018-09-05 | Новартис Аг | Способы лечения псориаза с использованием антагонистов il-17 |
| TWI616204B (zh) | 2010-11-05 | 2018-03-01 | 諾華公司 | Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途 |
| WO2012082573A1 (en) * | 2010-12-13 | 2012-06-21 | Novartis Ag | Predictive methods and methods of treating arthritis using il-17 antagonists |
| KR20140097178A (ko) | 2011-11-21 | 2014-08-06 | 노파르티스 아게 | IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법 |
| KR20150010709A (ko) | 2012-04-20 | 2015-01-28 | 노파르티스 아게 | Il-17 길항제를 사용하는 강직성 척추염의 치료 방법 |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| JP6858766B2 (ja) | 2015-10-19 | 2021-04-14 | ノバルティス アーゲー | インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法 |
| US11280479B2 (en) | 2017-10-18 | 2022-03-22 | The Sloan Company | Sign box light module |
-
2011
- 2011-11-04 TW TW104103341A patent/TWI616204B/zh active
- 2011-11-04 DE DE20187001.1T patent/DE20187001T1/de active Pending
- 2011-11-04 KR KR1020157003096A patent/KR20150020734A/ko not_active Ceased
- 2011-11-04 US US13/877,585 patent/US9744234B2/en active Active
- 2011-11-04 PL PL16163440T patent/PL3111954T3/pl unknown
- 2011-11-04 CN CN2011800529537A patent/CN103189074A/zh active Pending
- 2011-11-04 HU HUE16163440A patent/HUE044038T2/hu unknown
- 2011-11-04 TW TW100140410A patent/TWI604851B/zh active
- 2011-11-04 EP EP22180976.7A patent/EP4116325B1/en active Active
- 2011-11-04 CN CN201510199026.8A patent/CN104800844A/zh active Pending
- 2011-11-04 ES ES20187001T patent/ES2804624T3/es active Active
- 2011-11-04 LT LTEP20187001.1T patent/LT3757126T/lt unknown
- 2011-11-04 RU RU2013125775/15A patent/RU2582937C2/ru active
- 2011-11-04 KR KR1020187034385A patent/KR20180129991A/ko not_active Ceased
- 2011-11-04 PH PH1/2013/500890A patent/PH12013500890A1/en unknown
- 2011-11-04 EP EP16163440.7A patent/EP3111954B1/en not_active Revoked
- 2011-11-04 CA CA2813849A patent/CA2813849C/en active Active
- 2011-11-04 PT PT201870011T patent/PT3757126T/pt unknown
- 2011-11-04 DK DK16163440.7T patent/DK3111954T3/da active
- 2011-11-04 TR TR2019/09531T patent/TR201909531T4/tr unknown
- 2011-11-04 JP JP2013537154A patent/JP2014503482A/ja active Pending
- 2011-11-04 EP EP21180656.7A patent/EP3912640B1/en active Active
- 2011-11-04 TW TW105142587A patent/TWI618543B/zh active
- 2011-11-04 WO PCT/EP2011/069476 patent/WO2012059598A2/en not_active Ceased
- 2011-11-04 EP EP11778903.2A patent/EP2635303A2/en not_active Withdrawn
- 2011-11-04 KR KR1020167014431A patent/KR20160067984A/ko not_active Ceased
- 2011-11-04 SM SM20250423T patent/SMT202500423T1/it unknown
- 2011-11-04 RS RS20251090A patent/RS67377B1/sr unknown
- 2011-11-04 DK DK20187001.1T patent/DK3757126T3/da active
- 2011-11-04 HR HRP20251174TT patent/HRP20251174T1/hr unknown
- 2011-11-04 SI SI201132138T patent/SI3757126T1/sl unknown
- 2011-11-04 SG SG10201505624VA patent/SG10201505624VA/en unknown
- 2011-11-04 PT PT16163440T patent/PT3111954T/pt unknown
- 2011-11-04 EP EP19162707.4A patent/EP3542820A1/en not_active Withdrawn
- 2011-11-04 SG SG2013023064A patent/SG189138A1/en unknown
- 2011-11-04 LT LTEP16163440.7T patent/LT3111954T/lt unknown
- 2011-11-04 MX MX2013005060A patent/MX362591B/es active IP Right Grant
- 2011-11-04 KR KR1020187004058A patent/KR20180019247A/ko not_active Ceased
- 2011-11-04 FI FIEP20187001.1T patent/FI3757126T3/fi active
- 2011-11-04 EP EP20187001.1A patent/EP3757126B1/en active Active
- 2011-11-04 SI SI201131750T patent/SI3111954T1/sl unknown
- 2011-11-04 IL IL311014A patent/IL311014A/en unknown
- 2011-11-04 AU AU2011325134A patent/AU2011325134B2/en not_active Expired - Fee Related
- 2011-11-04 BR BR112013011176-3A patent/BR112013011176A2/pt not_active IP Right Cessation
- 2011-11-04 KR KR1020137011539A patent/KR20140008305A/ko not_active Ceased
- 2011-11-04 ES ES16163440T patent/ES2733712T3/es active Active
- 2011-11-04 CA CA3116725A patent/CA3116725C/en active Active
- 2011-11-04 ES ES21180656T patent/ES3030036T3/es active Active
-
2013
- 2013-03-18 IL IL225309A patent/IL225309B/en active IP Right Grant
- 2013-05-03 CL CL2013001213A patent/CL2013001213A1/es unknown
- 2013-05-03 MA MA35873A patent/MA34647B1/fr unknown
-
2015
- 2015-11-30 JP JP2015232562A patent/JP6049843B2/ja active Active
-
2016
- 2016-07-14 JP JP2016139469A patent/JP6250109B2/ja active Active
-
2017
- 2017-07-20 US US15/654,854 patent/US10363307B2/en active Active
- 2017-11-21 JP JP2017223669A patent/JP6515168B2/ja active Active
-
2018
- 2018-10-24 IL IL262559A patent/IL262559B/en unknown
-
2019
- 2019-04-12 JP JP2019076324A patent/JP2019142912A/ja active Pending
- 2019-06-12 US US16/439,423 patent/US20190307880A1/en not_active Abandoned
- 2019-06-26 HR HRP20191162TT patent/HRP20191162T1/hr unknown
- 2019-07-03 CY CY20191100708T patent/CY1121802T1/el unknown
-
2020
- 2020-03-19 US US16/824,613 patent/US11534491B2/en active Active
- 2020-12-18 US US17/127,758 patent/US20210128726A1/en not_active Abandoned
-
2021
- 2021-02-02 US US17/165,729 patent/US20210177966A1/en not_active Abandoned
- 2021-03-01 JP JP2021031383A patent/JP2021104995A/ja active Pending
- 2021-04-25 IL IL282625A patent/IL282625A/en unknown
- 2021-12-08 US US17/545,894 patent/US12465635B2/en active Active
-
2022
- 2022-10-21 US US18/048,797 patent/US20230293683A1/en active Pending
- 2022-12-02 US US18/061,221 patent/US20230346926A1/en active Pending
-
2023
- 2023-05-23 JP JP2023084472A patent/JP2023109910A/ja active Pending
-
2025
- 2025-02-24 US US19/061,831 patent/US12594333B2/en active Active
- 2025-03-04 JP JP2025034128A patent/JP2025102772A/ja active Pending
- 2025-11-14 US US19/389,528 patent/US20260077042A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013125775A (ru) | Способы лечения ревматоидного артрита с применением антагонистов il-17 | |
| ES2888224T3 (es) | Anticuerpos humanos contra PD-1 | |
| JP2011522832A5 (enExample) | ||
| JP2016065094A5 (enExample) | ||
| JP2018537962A5 (enExample) | ||
| US20200069797A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
| JP2019521647A5 (enExample) | ||
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| ES2769123T3 (es) | Anticuerpos de quimiocinas PAN ELR+ CXC | |
| US20230203152A1 (en) | Engineered anti-il-2 antibodies | |
| JP2016519650A5 (enExample) | ||
| AU2012312225B2 (en) | Cachexia treatment | |
| Semerano et al. | Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020528750A5 (enExample) | ||
| RU2015104001A (ru) | Комбинированная терапия для лечения глиобластомы | |
| JP2015521607A5 (enExample) | ||
| JP2017031213A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| JP2015007098A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2013535190A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| RU2016109448A (ru) | Комбинированная терапия для лечения глиобластомы | |
| JP2015535828A5 (enExample) |